stockrow
Friday 6 November 2026
Export CNSP’s income statement to Excel — free account
CNS Pharmaceuticals, Inc.
CNSP Healthcare Biotechnology
- EPS
- +94.1%
- Free cash flow
- +33.7%
Quarter to June 2026, against a year earlier
3.89
0.12
−2.99%
Follow CNSP
Alert me
CNS Pharmaceuticals, Inc. (CNSP) P/E ratio
CNS Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CRIS Curis, Inc. compare | n/m |
| APRE Aprea Therapeutics, Inc. compare | n/m |
| LGVN Longeveron Inc. compare | n/m |
| CNSP CNS Pharmaceuticals, Inc. | n/m |
| ENVB Enveric Biosciences, Inc. compare | n/m |
| EVGN Evogene Ltd. compare | n/m |
| XCUR Exicure, Inc. compare | n/m |
| AIM AIM ImmunoTech Inc. compare | n/m |
| ORGS Orgenesis Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)